<DOC>
	<DOCNO>NCT00004915</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth endometrial cancer cell . Hormone therapy use raloxifene may fight endometrial cancer reduce production estrogen . PURPOSE : Phase II trial study effectiveness raloxifene treat patient persistent recurrent endometrial cancer .</brief_summary>
	<brief_title>Raloxifene Treating Patients With Persistent Recurrent Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate time disease progression patient recurrent endometrial cancer treat raloxifene . II . Determine overall survival patient treat regimen . III . Determine toxicity raloxifene patient population . OUTLINE : Patients receive oral raloxifene daily . Treatment continue indefinitely absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 13-50 patient accrue study within 2.5 year .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Recurrent endometrial cancer Evidence persistent recurrent disease 4 week follow primary treatment radiation surgery Bidimensionally measurable disease Not candidate curative salvage radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 03 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular : No history unexplained uncontrolled thromboembolic disease No active thromboembolic disease Other : No active uncontrolled second malignancy HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy early stage advance endometrial cancer Endocrine therapy : At least 4 week since prior hormonal therapy early stage advance endometrial cancer Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>recurrent endometrial carcinoma</keyword>
</DOC>